Skip to content

LOGIC-Insulin Algorithm-guided Versus Nurse-directed Blood Glucose Control During Critical Illness

LOGIC-Insulin Computerized Algorithm-guided Versus Nurse-directed Blood Glucose Control in Critically Ill Patients: the LOGIC-1 Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01420302
Acronym
LOGIC-1
Enrollment
300
Registered
2011-08-19
Start date
2011-08-31
Completion date
2012-03-31
Last updated
2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical Illness

Keywords

critical illness, intensive care, insulin, glucose, algorithm, blood glucose control

Brief summary

The LOGIC-Insulin computerized software algorithm will be compared with a nurse-directed protocol, both targeting a blood glucose level of 80-110 mg/dL, in critically ill patients

Detailed description

Critical illness typically causes elevated blood glucose concentrations, which have been associated with increased mortality. Strictly normalizing these blood glucose levels by intensive insulin therapy, called tight glycemic control, decreased morbidity and mortality in well-controlled single-center clinical studies. However, multi-center pragmatic trials failed to reproduce those effects, proving that the implementation of tight glycemic control in daily clinical practice is rather difficult. A computerized algorithm, amongst others, may help the nurses in the titration of insulin to reach normal blood glucose levels and to avoid the particularly worrisome hypoglycemia. The LOGIC-1 study is a single blinded randomized controlled trial. On admission patients will be randomly assigned to either tight glycemic control (80-110 mg/dL) by the computerized LOGIC-Insulin 3.0 algorithm or to tight glycemic control (80-110 mg/dL) by the nurse-directed protocol. Written informed consent will be asked from the patient in the case of elective surgery requiring post-operative ICU-admission. Proxy informed consent from the closest family member will be asked when the patient was admitted to the ICU in emergency. As blood glucose control by itself is essential in the management of critical illness, random allocation will be done on admission and written informed consent from the closest family member can be deferred to a maximum of 24 hours after randomization. The patient or family member can at all times withdraw from the trial without impact on his treatment. Allocation will be done in blocks (block size is unknown to the care givers responsible for treatment allocation), stratified into cardiac surgery and other reasons for ICU admission, by central computer randomization. The time window for the study will be 14 days starting from admission to the ICU or when one of the following stop criteria will be met: * Withdrawal of the informed consent * Patient starts eating or drinking sugar containing liquids * Patient is discharged from the ICU (including ICU deaths) * Removal of arterial line or central venous line Under the following conditions the study investigator/treating physician will be contacted and, if necessary, patients will be switched from LOGIC-Insulin to nurse-directed blood glucose control: * Recurrent severe hypoglycemia (\<40 mg/dL) * Refractory hyperglycemia * Any change in condition that compromises the safety of the patient, as judged by the investigator or treating physician The common strategy for blood glucose control in both groups involves blood glucose measurements from arterial blood by a blood gas analyzer and the administration of insulin through a central line with a syringe pump.

Interventions

PROCEDURENurse directed

Nurse directed insulin titration to establish glycemic control in the target range of 80-110 mg/dL

PROCEDURELOGIC-Insulin

Blood glucose control (80-110 mg/dL) guided by the LOGIC-Insulin algorithm

Sponsors

Agency for Innovation by Science and Technology, Flanders, Belgium
CollaboratorUNKNOWN
Fund for Scientific Research, Flanders, Belgium
CollaboratorOTHER
Greet Van den Berghe
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Intervention model description

Algorithm-guided versus Nurse directed Blood Glucose Control

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Aged 18 years or more * Admitted to the ICU * Already receiving or needing insulin infusion for blood glucose control

Exclusion criteria

* Not critically ill (eating, not mechanically ventilated) * Pregnant or breastfeeding * Previous inclusion into the trial * Included in other trial * Moribund * Diabetes coma * No arterial line available

Design outcomes

Primary

MeasureTime frameDescription
Glycemic Penalty Index (GPI) During the InterventionThe GPI is the average of all penalties that are individually assigned to all blood glucose values obtained up to 14 days post-randomization, based on an optimized smooth penalty function.The GPI is an index (ranging from 0 to 100) derived from the blood glucose values that are outside the target level of 80-110 mg/dL, in both the hyperglycemic and the hypoglycemic ranges. The weight of the penalty score of a blood glucose measurement is proportional to the level of deviation from normoglycemia. The GPI is the average of all penalties that are individually assigned to all blood glucose values, based on an optimized smooth penalty function. Higher GPI scores indicate lower efficacy of glycemic control.

Secondary

MeasureTime frameDescription
Incidence of Severe Hypoglycemia (<40 mg/dL) During the Interventionup to 14 days post-randomizationNumber of severe hypoglycemic values as a fraction of all blood glucose measurements during the intervention
Blood Glucose Level Per Treatment Group During the Interventionup to 14 days post-randomization
Hyperglycemic Index (HGI) During the Interventionup to 14 days post-randomizationAdequacy of reaching and maintaining the target range for blood glucose during the intervention
Daily Maximal Blood Glucose Difference During the Interventionup to 14 days post-randomizationMarker of blood glucose variability
Proportion of Patients With Common Hypoglycemia (<60 mg/dL) During the Interventionup to 14 days post-randomizationProportion of patients to have had one or more episodes of common hypoglycemia during the intervention
Proportion of Patients With Severe Hypoglycemia (<40 mg/dL) During the Interventionup to 14 days post-randomizationProportion of patients to have had one or more episodes of severe hypoglycemia (\<40 mg/dL) during the intervention
Percentage of Time in Target Zone (80-110 mg/dL) During the Interventionup to 14 days post-randomizationAdequacy of reaching and maintaining the target range for blood glucose during the intervention
Length of Stay in ICUup to 90 days post-randomization
Length of Stay in Hospitalup to 90 days post-randomization
Hospital Mortalityup to 90 days post-randomizationPatients who will have been discharged from hospital before 90 days post-randomization will be regarded as survivors
Incidence of Common Hypoglycemia (<60 mg/dL) During the Interventionup to 14 days post-randomizationNumber of common hypoglycemic values as a fraction of all blood glucose measurements during the intervention
Interval Between Blood Glucose Measurements During the Interventionup to 14 days post-randomizationMarker of workload

Countries

Belgium

Participant flow

Recruitment details

Patients were recruited from 22 August 2011 to 16 December 2011 in a 56-bed ICU of a tertiary referral university hospital

Participants by arm

ArmCount
LOGIC-Insulin
Blood glucose control (80-110 mg/dL) guided by the LOGIC-Insulin algorithm
149
Nurse-directed
Nurse-directed blood glucose control (80-110 mg/dL)
151
Total300

Baseline characteristics

CharacteristicTotalLOGIC-InsulinNurse-directed
Admission type
After cardiac surgery
150 Participants76 Participants74 Participants
Admission type
Medical
49 Participants26 Participants23 Participants
Admission type
Other surgery
57 Participants28 Participants29 Participants
Admission type
Transplantation
44 Participants19 Participants25 Participants
Age, Continuous63 years
STANDARD_DEVIATION 15
65 years
STANDARD_DEVIATION 15
62 years
STANDARD_DEVIATION 14
Apache II score (mean SD)23 units on a scale
STANDARD_DEVIATION 11
23 units on a scale
STANDARD_DEVIATION 10
24 units on a scale
STANDARD_DEVIATION 10
BMI (kg/m²)26.2 kg/m²
STANDARD_DEVIATION 5.2
26.5 kg/m²
STANDARD_DEVIATION 5.5
25.9 kg/m²
STANDARD_DEVIATION 4.8
Diabetes64 Participants32 Participants32 Participants
Region of Enrollment
Belgium
300 participants149 participants151 participants
Sex: Female, Male
Female
119 Participants61 Participants58 Participants
Sex: Female, Male
Male
181 Participants88 Participants93 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
19 / 14910 / 151
other
Total, other adverse events
0 / 1490 / 151
serious
Total, serious adverse events
0 / 1490 / 151

Outcome results

Primary

Glycemic Penalty Index (GPI) During the Intervention

The GPI is an index (ranging from 0 to 100) derived from the blood glucose values that are outside the target level of 80-110 mg/dL, in both the hyperglycemic and the hypoglycemic ranges. The weight of the penalty score of a blood glucose measurement is proportional to the level of deviation from normoglycemia. The GPI is the average of all penalties that are individually assigned to all blood glucose values, based on an optimized smooth penalty function. Higher GPI scores indicate lower efficacy of glycemic control.

Time frame: The GPI is the average of all penalties that are individually assigned to all blood glucose values obtained up to 14 days post-randomization, based on an optimized smooth penalty function.

ArmMeasureValue (MEDIAN)
LOGIC-InsulinGlycemic Penalty Index (GPI) During the Intervention9.8 units on a scale
Nurse-directedGlycemic Penalty Index (GPI) During the Intervention12.4 units on a scale
p-value: <0.0001Wilcoxon (Mann-Whitney)
Secondary

Blood Glucose Level Per Treatment Group During the Intervention

Time frame: up to 14 days post-randomization

Secondary

Daily Maximal Blood Glucose Difference During the Intervention

Marker of blood glucose variability

Time frame: up to 14 days post-randomization

Secondary

Hospital Mortality

Patients who will have been discharged from hospital before 90 days post-randomization will be regarded as survivors

Time frame: up to 90 days post-randomization

Secondary

Hyperglycemic Index (HGI) During the Intervention

Adequacy of reaching and maintaining the target range for blood glucose during the intervention

Time frame: up to 14 days post-randomization

Secondary

Incidence of Common Hypoglycemia (<60 mg/dL) During the Intervention

Number of common hypoglycemic values as a fraction of all blood glucose measurements during the intervention

Time frame: up to 14 days post-randomization

Secondary

Incidence of Severe Hypoglycemia (<40 mg/dL) During the Intervention

Number of severe hypoglycemic values as a fraction of all blood glucose measurements during the intervention

Time frame: up to 14 days post-randomization

Secondary

Interval Between Blood Glucose Measurements During the Intervention

Marker of workload

Time frame: up to 14 days post-randomization

Secondary

Length of Stay in Hospital

Time frame: up to 90 days post-randomization

Secondary

Length of Stay in ICU

Time frame: up to 90 days post-randomization

Secondary

Percentage of Time in Target Zone (80-110 mg/dL) During the Intervention

Adequacy of reaching and maintaining the target range for blood glucose during the intervention

Time frame: up to 14 days post-randomization

Secondary

Proportion of Patients With Common Hypoglycemia (<60 mg/dL) During the Intervention

Proportion of patients to have had one or more episodes of common hypoglycemia during the intervention

Time frame: up to 14 days post-randomization

Secondary

Proportion of Patients With Severe Hypoglycemia (<40 mg/dL) During the Intervention

Proportion of patients to have had one or more episodes of severe hypoglycemia (\<40 mg/dL) during the intervention

Time frame: up to 14 days post-randomization

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026